These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 2417654)

  • 1. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
    Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
    Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset.
    Jenner P; Taquet H; Mauborgne A; Benoliel JT; Cesselin F; Rose S; Javoy-Agid F; Agid Y; Marsden CD
    J Neurochem; 1986 Nov; 47(5):1548-51. PubMed ID: 2428937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
    Waters CM; Hunt SP; Jenner P; Marsden CD
    Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment.
    Taquet H; Nomoto M; Rose S; Jenner P; Javoy-Agid F; Mauborgne A; Benoliel JJ; Marsden CD; Legrand JC; Agid Y
    Neuropeptides; 1988 Oct; 12(3):105-10. PubMed ID: 2468106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
    Pifl C; Schingnitz G; Hornykiewicz O
    Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
    Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
    Taylor MD; de Ceballos ML; Rose S; Chong PN; Jenner P; Marsden CD
    J Neural Transm Park Dis Dement Sect; 1991; 3(2):99-108. PubMed ID: 1716907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
    Garvey J; Petersen M; Waters CM; Rose SP; Hunt S; Briggs R; Jenner P; Marsden CD
    Mov Disord; 1986; 1(2):129-34. PubMed ID: 3143064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T
    Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
    Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
    Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
    Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
    Ueki A; Chong PN; Albanese A; Rose S; Chivers JK; Jenner P; Marsden CD
    Neuropharmacology; 1989 Oct; 28(10):1089-97. PubMed ID: 2510050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
    Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H
    Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry.
    Schneider JS; Yuwiler A; Markham CH
    Exp Neurol; 1986 Feb; 91(2):293-307. PubMed ID: 3484707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset.
    Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
    Eur J Pharmacol; 1990 May; 181(1-2):97-103. PubMed ID: 2117541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.